Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Sep;82(3):165-171.
doi: 10.1016/j.jjcc.2023.04.003. Epub 2023 Apr 6.

Impact of right coronary artery dominance on the long-term mortality in the patients with acute total/subtotal occlusion of unprotected left main coronary artery

Makoto Iwama  1 , Toshiyuki Noda  2 , Kensuke Takagi  3 , Akihito Tanaka  4 , Yusuke Uemura  5 , Norio Umemoto  6 , Naoki Shibata  7 , Yosuke Negishi  8 , Taiki Ohashi  9 , Miho Tanaka  10 , Ruka Yoshida  11 , Kiyokazu Shimizu  6 , Hiroshi Tashiro  12 , Naoki Yoshioka  13 , Itsuro Morishima  3 , Masato Watarai  5 , Toshikazu Tanaka  14 , Yosuke Tatami  9 , Yasunobu Takada  10 , Hideki Ishii  15 , Toyoaki Murohara  4 ; N-registry investigators
Affiliations
Free article
Multicenter Study

Impact of right coronary artery dominance on the long-term mortality in the patients with acute total/subtotal occlusion of unprotected left main coronary artery

Makoto Iwama et al. J Cardiol. 2023 Sep.
Free article

Abstract

Background: Patients with a right dominant coronary artery anatomy account for a significant proportion of acute myocardial infarction cases, and this condition is associated with a better prognosis. However, there are limited data on the impact of coronary dominance on patients with acute total/subtotal occlusion of unprotected left main coronary artery (ULMCA).

Methods: This study aimed to assess the impact of right coronary artery (RCA) dominance on long-term mortality in patients with acute total/subtotal occlusion of the ULMCA. From a multicenter registry, 132 cases of consecutive patients who had undergone emergent percutaneous coronary intervention (PCI) due to acute total/subtotal occlusion of the ULMCA were reviewed.

Results: Patients were classified into two groups according to the size of their RCA (dominant RCA group, n = 29; non-dominant RCA group, n = 103). Long-term outcomes were examined according to the presence of dominant RCA. Cardiopulmonary arrest (CPA) occurred in 52.3 % of patients before revascularization. All-cause death was significantly lower in the dominant RCA group than in the non-dominant RCA group. In the Cox regression model, dominant RCA was an independent predictor of all-cause death, as well as total occlusion of ULMCA, collateral from RCA, chronic kidney disease, and CPA. Patients were further analyzed according to the degree of stenosis of the ULMCA; patients with non-dominant RCA and total occlusive ULMCA had the worst outcome compared with the other groups.

Conclusions: A dominant RCA might improve long-term mortality in patients with acute total/subtotal occlusion of the ULMCA who were treated with PCI.

Keywords: Acute myocardial infarction; Percutaneous coronary intervention; Prognosis; Right coronary dominance; Unprotected left main coronary artery disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Hideki Ishii received lecture fees from Astellas Pharma Inc., Astrazeneca Inc., Daiichi-Sankyo Pharma Inc., and MSD. K. K. Yusuke Uemura received lecture fees from Otsuka Pharma Ltd. Itsuro Morishima received lecture fees from Daiichi-Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Abbott Japan. Makoto Iwama received lecture fees from Daiichi-Sankyo Co., Ltd., Abbott Japan, Terumo Co., Ltd., and Boston Scientific Co., Ltd. Toyoaki Murohara received lecture fees from Bayer Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD. K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-Aventis K. K., and Takeda Pharmaceutical Co., Ltd. Toyoaki Murohara received an unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis K. K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. All other authors declare no conflicts of interest.

Comment in

Publication types

LinkOut - more resources